{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074972","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.010725+00:00","generated_at":"2026-05-17T17:24:16.741975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ironwood Pharmaceuticals Reports Q2 2025 Results; LINZESS U.S. Net Sales $248M, GAAP Net Income $23.6M","bullets":["LINZESS generated $248M in U.S. net sales in Q2 2025, with 10% year-over-year EUTRx demand growth.","GAAP net income was $23.6M in Q2 2025, compared to a net loss of $0.9M in Q2 2024.","Adjusted EBITDA was $50.1M in Q2 2025, up from $36.5M in Q2 2024.","Company plans to align with FDA on confirmatory Phase 3 trial design for apraglutide in Q4 2025.","Ironwood is actively progressing a strategic alternatives review to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074972","json":"https://secwatch.observer/filing/0001104659-25-074972.json","markdown":"https://secwatch.observer/filing/0001104659-25-074972.md","text":"https://secwatch.observer/filing/0001104659-25-074972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/0001104659-25-074972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/tm2522671d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T17:24:16.741975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}